Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep;23 Suppl 10(Suppl 10):x231-6.
doi: 10.1093/annonc/mds324.

Neoadjuvant treatment of breast cancer

A M Thompson  1 , S L Moulder-Thompson
Affiliations

Neoadjuvant treatment of breast cancer

A M Thompson et al. Ann Oncol. 2012 Sep.

Abstract

Neoadjuvant treatment of breast cancer has become established as the safe and often effective therapeutic approach of choice for larger primary and for locally advanced breast cancer. The neoadjuvant approach offers the advantages of downstaging the disease, potentially reducing the extent of surgery and in an era of individualization of therapy, testing the efficacy of therapy administered to patients. The preoperative setting is also an effective way to study the activity of novel agents or therapeutic combinations in vivo against human breast cancer. For new therapies, preoperative trials avoid the issue of adaptive resistance and pretreatments that can be problematic in the advanced disease setting. For evidence of a drug targeting the cancer in vivo, comparisons of endocrine therapy, chemotherapy agents and/or targeted agents can provide data on activity and efficacy with a much shorter time frame and many fewer patients than for adjuvant trials; effects seen in neoadjuvant trials may even reflect what is found in the adjuvant setting. Patient benefits from the neoadjuvant approach may be greatest for those who experience complete pathologically documented response (and the consequent survival benefits) and women for whom breast conservation, rather than mastectomy, becomes possible.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kuerer HM, Newman La, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460–469. - PubMed
    1. Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathological complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006;24:1037–1044. doi: 10.1200/JCO.2005.02.6914. - DOI - PubMed
    1. Deo SV, Bhutani M, Shukla NK, et al. Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0–2 M0) J Surg Oncol. 2003;84(4):192–197. - PubMed
    1. Mieog JSD, van der Hage Ja, van de Velde CJH. Neoadjuvant chemotherapy for opérable breast cancer. Br J Surg. 2007;94:1198–1200. - PubMed
    1. Shet T, agrawal a, Chinoy R, et al. Changes in the tumor grade and biological markers in locally advanced breast cancer after chemotherapy—implications for a pathologist. Breast J. 2007;13(5):457–464. doi: 10.1111/j.1524-4741.2007.00465.x. - DOI - PubMed